Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) [Phase 1]

View source ↗

Summary

Phase 1 LOTIS-10 study assessing the pharmacokinetics and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma or high-grade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma

Drugs mentioned

• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Status: RECRUITING